Dr Brian Tse

BMedSc(Hon), DipInnovMan, PhD (all UNSW)

Senior Preclinical Imaging Scientist

Projects

Preclinical Imaging: Ultrasound and Photoacoustics, Positron Emission Tomography and Computed Tomography (PET-CT), Optical Imaging (bioluminescence & fluorescence), X-Ray, Nuclear Magnetic Resonance (NMR)

About me

Dr Brian Tse, Senior Preclinical Imaging Scientist (Facility Manager) of the Preclinical Imaging Core Facility (2015-), provides expertise (technical and knowledge) to researchers on in vivo imaging. He currently manages seven high-end preclinical imaging instrumentations; 1) Fujifilm Visualonics Vevo LAZR (Ultrasound and Photoacoustics), 2) Siemens Inveon Multi-modality (microPositron Emission Tomography-Computed Tomography), 3) Perkin ElmerIVIS Spectrum (Optical Imaging), 4) Bruker Minispec LF50H (Nuclear Magnetic Resonance), 5) Lions Australia Bruker Skyscan 1272 (ultra-high resolution microCT), 6) Faxitron Ultrafocus 100 (Planar X-ray), and 7) Perkin Elmer Wizard 2480 (gamma counting).

Dr Tse obtained his PhD from the University of New South Wales in 2011 in the field of cancer immunotherapy, where he also gained expertise in cutting-edge imaging modalities (optical imaging, ultrasound and microCT). He then undertook a two-year post-doctoral position at the Lowy Cancer Research Centre in Sydney before moving to Brisbane in 2012 to join QUT-IHBI to work on several projects including prostate cancer imaging, and elucidating the molecular drivers of disease progression. Dr Tse has received funding from the US Department of Defence (Post-doc Fellowship), NHMRC (Project grant) and QUT-IHBI (ECR grant). He has been managing the Preclinical Imaging Facility since late 2015, and has particular research interests in the application of photoacoustics, high-frequency ultrasound, microCT and microPET-CT to study diseases.

Funding sources:

2016-2018   NHMRC Project Grant                                             $561,012             CIA Doran, CIB Vela, CIC Tse, CID Russell

2016             QUT IHBI ECR grant                                                 $10,000               Tse

2014-2016   USA Department of Defence (DOD) Fellowship $124,056 (USD)  Tse

 

Publications

13. Wang H, Li X, Tse BW-C, Yang H, Thorling CA, Liu Y, Touraud M, Chouane JB, Liu X, Roberts MS, Liang X. Indocyanine green-incorporating nanoparticles for cancer theranostics. Theranostics 2018; 8(5):1227-1242.

12. Tse BW-C*, Volpert M*, Ratther E*, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler M, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC & Hollier BG. Neuropilin-1 is up-regulated in the adaptive response of prostate tumors to androgen targeted therapies and is prognostic of metastastic progression and patient mortality. Oncogene. 2017. doi: 10.1038/onc.2016.482. * Equal first.

11. Rhee H, Ng KL, Tse BW-C, Yeh MC, Russell PJ, Nelson CC, Samaratunga H, Thomas, T, Vela I, Gobe G, Wood S. Using Prostate Specific Membrane Antigen (PSMA) Expression In Clear Cell Renal Cell Carcinoma For Imaging Advanced Disease. Pathology. 2016. doi: 10.1016/j.pathol.2016.05.011

10. Fuchs AV*, Tse BW-C*, Pearce AK, Yeh MC, Fletcher N, Huang SS, Heston WD, Whittaker AK, Russell PJ, Thurecht K. Evaluation of polymeric nanomedicines targeted to PSMA: Effect of ligand on targeting efficiency.Biomacromolecules. 2015: 16 (10), pp 3235–3247  doi10.1021/acs.biomac.5b00913. *Equal first.

9.  Russell PJ, Russell P, Rudduck C, Tse BW-C, Williams ED. Raghavan D. Establishing prostate cancer patient derived xenografts: lessons learned from older studies. The Prostate. 2015. doi: 10.1002/pros.22946

8. Tse BW-C, Cowin G, Soekmadji C, Jovanovic L, Vasireddy RS, Ling M-T, Khatri A, Liu TQ, Thierry B, Russell PJ. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine. 2014. doi: 10.2217/NNM.14.122.

7. Pearce AK, Rolfe B, Russell PJ, Tse BW-C, Whittaker AK, Fuchs AV, Thurecht KJ. Development of a polymer theranostic for prostate cancer. Polymer Chemistry. 2014doi:10.1039/C4PY00999A.

6. Tse BW-C, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ. From bench to bedside: immunotherapy for prostate cancer. Biomed Research International 2014. Article ID 981434, 11 pages. doi:10.1155/2014/981434.

5. Jacob F, Anugraham M, Alam S, Tse BW-C, Pochechueva T, Guertler R, Bovin NV, Fedier A, Hacker NF, Huflejt MF, Packer N, Heinzelmann-Schwarz V. The Glycosphingolipid P1 Is an Ovarian Cancer-Associated Carbohydrate Antigen Involved in Migration. British Journal of Cancer. 2014. doi: 10.1038/bjc.2014.455

4. Tse BW-C, Collins A, Oehler MK, Collins A, Zipplelius A, Heinzelmann-Schwarz V. Antibody-based immunotherapy for ovarian cancer – where are we at? Annals of Oncology. 2013. doi:10.1093/annonc/mdt405

3. Buehler M, Tse BW-C, Leboucq A, Jacob F, Caduff R, Fink D, Goldstein D, Heinzelmann-Schwarz V. Meta-analysis of microarray data identifies GAS6 as an independent predictor of poor survival in ovarian cancer, BioMed Research International, 2013, Article ID 238284, 9 pages, 2013. doi:10.1155/2013/238284

2. Tse BW-C, Scott KF, Russell PJ. Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology.Prostate Cancer. 2012; Article ID 128965, 8 pages. doi:10.1155/2012/128965

1. Tse BW-C, Russell PJ, Lochner M, Forster I, Power CA.  IL-18 Inhibits Growth of Murine Orthotopic Prostate Carcinomas via Both Adaptive and Innate Immune Mechanisms. PLoS ONE  2011; 6(9):e24241. doi:10.1371/journal.pone.0024241

 

 

Research fields

Preclinical Imaging